# GSK plc 9.7% potential upside indicated by Barclays

- Link: https://www.directorstalkinterviews.com/gsk-plc-9.7-potential-upside-indicated-by-barclays/4121132468
- Published: 2023-11-09T13:27:13+00:00
- Author: Charlotte Edwards

**[GSK plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)**
with ticker ([LON:GSK](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l))
now has a potential upside of 9.7% according to Barclays.
Barclays set a target 
price of 1,575 GBX for the company, which when compared to the GSK plc share price
of 1,436 GBX at opening today (09/11/2023) indicates a potential upside of 9.7%.
Trading has ranged between 1,303 (52 week low) and 1,609 (52 week high) with an 
average of 6,174,442 shares exchanging hands daily. The market capitalisation at
the time of writing is £58,477,071,240.GSK plc is a global biopharma company. The
Company’s segments include Commercial Operations and Research and Development. It
develops cancer medicines for patients, including ovarian cancer, endometrial cancer,
and multiple myeloma. It has developed monoclonal antibodies to help treat different
diseases. Its product areas include vaccines, specialty medicines, and general medicine.
Its vaccine portfolio includes more than 20 vaccines that help protect people from
a range of diseases and infections throughout their lives. Its specialty medicines
include medicines for immune-mediated conditions. Its specialty medicines are also
engaged in developing medicines for respiratory disease and HIV. Its general medicines
include inhaled medicines for asthma and chronic obstructive pulmonary disease (
COPD), antibiotics, and medicines for skin diseases. The Company owns camlipixant,
a selective P2X3 antagonist, which is in Phase III development for the treatment
of refractory chronic cough (RCC).

Share on: